Kezar Life Sciences, Inc.

KZRSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1645666

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	$0.00	—	—	—
Research and Development Expense	$51.0M	$38.9M	$31.0M	$27.4M	$18.1M
Operating Expenses	$71.2M	$54.7M	$43.0M	$37.3M	$24.7M
Operating Income (Loss)	-$71.2M	-$54.7M	-$43.0M	-$37.3M	-$24.7M
Interest Expense	—	$159.0K	$0.00	$159.0K	—
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$68.2M	-$54.6M	-$41.7M	-$35.1M	-$23.2M
Earnings Per Share, Basic

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$221.2M	$299.6M	$217.9M	$151.8M	$89.5M
Assets, Current	$206.9M	$285.7M	$211.7M	$144.8M	$81.1M
Cash and Cash Equivalents, at Carrying Value	$35.5M	$40.5M	$62.9M	$21.2M	$15.0M
Liabilities	$33.7M	$29.7M	$21.1M	$10.9M	$11.5M
Liabilities, Current	$17.7M	$11.0M	$8.2M	$6.4M	$6.0M
Long-term Debt	—	$10.0M	$10.0M	$10.0M	—
Accounts Payable, Current	$8.3M	$2.5M	$2.0M	$2.4M	$823.0K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$58.8M	-$42.4M	-$36.9M	-$29.9M	-$20.8M
Net Cash Provided by (Used in) Investing Activities	-$91.4M	-$28.4M	-$56.5M	$20.4M	-$83.9M
Net Cash Provided by (Used in) Financing Activities	$127.9M	$112.6M	$99.6M	$272.0K	$77.9M
Payments to Acquire Property, Plant, and Equipment	$1.6M	$316.0K	$194.0K	$607.0K	$1.1M
Payments of Ordinary Dividends, Common Stock	$0.00	$0.00	$0.00	$0.00	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)